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Abstract  
Airways hyperresponsiveness and inflammation are fundamental hallmarks of allergic 
asthma and are accompanied by increases in certain polycations, such as eosinophil cationic 
protein, whose levels in body fluids correlate with asthma severity. Here we show that 
polycations, or elevated extracellular calcium activate the human recombinant and native 
calcium-sensing receptor (CaSR), leading to intracellular calcium mobilization, cAMP 
breakdown and p38 MAPK phosphorylation in airway smooth muscle (ASM) cells, effects 
prevented by CaSR antagonists, termed calcilytics. Asthmatic patients and allergen-sensitized 
mice expressed more CaSR in ASMs than their healthy counterparts. Polycations induced 
hyperreactivity in mouse bronchi, effect prevented by calcilytics and absent in mice with 
CaSR ablation from ASM. Calcilytics also reduced airway hyperresponsiveness and 
inflammation in allergen-sensitized mice in vivo. These data show that a functional CaSR is 
upregulated in asthmatic ASM and targeted by locally produced polycations to induce 
hyperresponsiveness and inflammation. Calcilytics may represent a novel, effective asthma 
therapeutics.  
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Introduction 
 
Despite substantial advances in our understanding of its pathophysiology and improved 
therapeutic regimens, asthma remains a tremendous worldwide healthcare burden with 
around 300 million individual sufferers. While the symptoms of asthma are potentially 
controllable in the majority of asthma sufferers using conventional therapy such as topical 
bronchodilators and corticosteroids, these are troublesome to administer efficiently and 
present unwanted side effects. Most importantly, there remains a significant minority of 
patients whose symptoms fail to be controlled with these approaches and who face 
chronically impaired quality of life with increased risk of hospital admission and even death. 
Although in a minority, such patients account for the major share of asthma healthcare costs. 
Accordingly, there is an urgent unmet need for identification of novel asthma therapies that 
target the root-cause of the disease, rather than its clinical sequelae. 
 
Asthma is characterized by inflammation-driven exaggeration of airway narrowing in 
response to specific and non-specific environmental stimuli (non-specific airway 
hyperresponsiveness, or AHR), as well as chronic remodeling of the conducting airways (1). 
A number of mechanisms, many driven by inflammation, have been hypothesized to 
contribute to AHR and/or remodeling. Among these, there is increasing recognition that 
airway inflammation results in augmented local concentrations of polycations (2-7). The 
polycations eosinophil cationic protein (ECP) and major basic protein are well-established 
markers for asthma severity and stability, with some evidence that they may contribute 
directly to the pathogenesis of asthma (6, 8-10). Furthermore, in asthma, increased arginase 
activity diverts L-arginine towards increased production of the polycations spermine, 
spermidine and putrescine (4, 5, 11). While in human peripheral blood monocytes spermine 
exhibits anti-inflammatory properties (12), Although such associations between increases in 
polycations in the asthmatic airway mucosa and AHR/airway remodeling and inflammation 
(4, 5, 13) have long been apparent and ascribed to their positive charge (9). However, the 
cause-effect relationship remains hitherto unexplained. Here, we provide evidence that 
activation of the cell-surface, G protein-coupled calcium-sensing receptor (CaSR) by 
polycations drives AHR and inflammation in allergic asthma.  
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The CaSR is the master controller of extracellular free ionized calcium ion (Ca
2+
o) 
concentration via the regulation of parathyroid hormone secretion (14). Accordingly, CaSR-
based therapeutics is employed for the treatment of systemic disorders of mineral ion 
metabolism. Pharmacological activators of the CaSR (calcimimetics) are used to treat 
hyperparathyroidism and negative allosteric modulators of the CaSR (calcilytics) are in 
clinical development for treating autosomal dominant hypocalcemia (15).  
 
In addition to its pivotal role in divalent cation homeostasis, the CaSR is expressed in tissues 
not involved in mineral ion metabolism such as the blood vessels, breast and placenta where 
the CaSR regulates many fundamental processes including gene expression, ion channel 
activity and cell fate (16). Furthermore, altered CaSR expression has also been associated 
with several pathological conditions including inflammation, vascular calcification, and 
certain cancers (16-19). In these non-calciotropic tissues, the CaSR responds to a range of 
stimuli including not only Ca
2+
o, but also polyvalent cations, amino acids, ionic strength and 
pH, making this receptor uniquely capable of integrating multiple environmental signals. 
Owing to its ability to act as a multimodal chemosensor, the potential relevance of CaSR to 
asthma pathophysiology is manifold, yet there is currently no evidence regarding CaSR 
expression or function in asthma. In this regard, a fundamental aspect of asthma 
pathophysiology is elevated intracellular calcium ion concentration ([Ca
2+
]i) in airway 
smooth muscle (ASM) cells that is critical not only to the enhanced bronchoconstriction of 
non-specific AHR but is also implicated in longer-term, likely genomic effects that result in 
airway remodeling such as increased ASM cell proliferation (leading to airway wall 
thickening) and deposition of extracellular matrix components (20, 21). There is currently no 
information as to whether the CaSR can regulate [Ca
2+
]i in the asthmatic airways, even 
though a polycation sensor such as the CaSR, whose activation leads to an increase in [Ca
2+
]i, 
seems a likely candidate. Therefore, we hypothesized that, if a CaSR was to be found in the 
airways, it would sense and respond not only to inflammation-enhanced Ca
2+
o, but also to 
polycations such as the ECPs and L-arginine-derived polyamines putrescine, spermidine and 
spermine, whose production is dramatically increased during asthma (3-7, 11) or by many 
RNA respiratory viruses that exacerbate asthma, such as influenza A and Newcastle disease 
virus, which either contain polyamines in the viral envelope or produce them as part of their 
requirement for replication (22, 23). To test our hypothesis, we examined human ASM 
samples from non-asthmatic and asthmatic subjects, and employed two models of allergen-
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induced airways inflammation, together with a mouse model of targeted CaSR gene ablation 
from ASM.  
 
Results 
 
CaSR expression in human and mouse airways is increased during asthma 
In human bronchial biopsies and in mouse interlobular bronchi, CaSR was immunolocalized 
within the SM22α-positive smooth muscle layer, with additional expression in bronchial 
epithelium (Fig. 1A). Isolated human and mouse ASM cells retained CaSR expression (Fig. 
1B).  
Quantitative RT-PCR and western analysis of human ASM cells demonstrated that both 
CaSR mRNA (Fig. 1C) and protein (Fig. 1D) expression were increased approximately three-
fold in moderate asthmatics, compared to non-asthmatics (“healthy”). Furthermore, in human 
ASM cells from healthy individuals, 48h exposure to the asthma-associated pro-
inflammatory cytokines, TNF and IL-13, significantly increased CaSR protein expression 
(Fig. 1E and Fig. S1C). qRT-PCR of laser-capture microdissected ASM layers of intralobular 
bronchi in lung sections showed approximately three-fold increase in CaSR mRNA 
expression in mixed allergen-sensitized mice, compared to ASM from unsensitized mice 
(Fig. 1F). Together, these results indicate that the CaSR is present in human and mouse ASM 
and its expression is increased in asthma. Furthermore, in vitro effects of cytokines on human 
ASM, and in the effects of mixed allergen sensitization in a mouse model of allergic asthma 
provide an evidence for the role of inflammation in upregulation of CaSR expression.  
  
Polycations implicated in asthma pathogenesis activate the human CaSR 
In many cell types, CaSR activation results in an increase in intracellular Ca
2+
 concentration 
([Ca
2+
]i) arising from mobilization of Ca
2+
i (14). To test the hypothesis that polycations that 
are upregulated during asthma activate the CaSR, we measured changes in [Ca
2+
]i in HEK293 
cells stably expressing the human CaSR (HEK-CaSR), or HEK293 cells stably expressing an 
empty vector (HEK-0). A representative western blot of HEK-CaSR and HEK-0 is shown in 
Fig. S2A. Consistent with this hypothesis, HEK-CaSR, but not HEK-0 cells, exhibited 
significant increases in [Ca
2+
]i following exposure to: i) eosinophil cationic protein (ECP, 10 
μg/ml, a concentration well below the cytotoxic levels (24) and comparable to those 
measured in the sputum of some asthmatic subjects (6, 7)); ii) the polycationic peptide poly-
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L-arginine (PLA, 300 nM; a mimetic of major basic protein (8)), and; iii) the polycation 
spermine (1 mM)(Fig. 2A and Fig. S2, B-D for single traces). For each of these agonists, the 
increase in [Ca
2+
]i was inhibited by the calcilytic NPS89636 (100 nM)(Fig. 2A and Fig. S2, 
B-D for single traces). Additional calcilytics, NPS2143 (1 µM) or Calhex 231 (1 µM), also 
prevented spermine-induced CaSR activation (Fig. 2A and Fig. S2D).  
 
Calcilytics prevent increases in Ca
2+
i in ASM from asthmatic patients 
In human ASM, several endogenously produced agents such as acetylcholine (ACh) and 
histamine evoke increases in [Ca
2+
]i, which drive AHR, remodeling and production of a range 
of inflammatory cytokines and other mediators in asthma (20, 25). Accordingly, we 
hypothesized that activation of CaSR in ASM also leads to an increase in [Ca
2+
]i, and 
predicted that this effect would be enhanced in asthmatics.  
We found that the sensitivity of human asthmatic ASM in the absence of agents that increase 
[Ca
2+
]i was significantly higher than those from non-asthmatics in the presence of 2 mM 
[Ca
2+
]o (Fig. 2B, left panel and Fig. S3A,B for single traces). Inhibition of the CaSR with the 
calcilytic NPS2143 (1 µM) blunted the [Ca
2+
]o hyper-responsiveness of asthmatic ASM cells, 
highlighting the functional role of CaSR in this setting (Fig. 2B, right panel and Fig. S3A,B 
for single traces).  
 
Having determined the sensitivity of human ASM to [Ca
2+
]o, we then tested the ability of the 
CaSR to alter [Ca
2+
]i responses to ACh in human asthmatic and healthy ASM. In the presence 
of physiological [Ca
2+
]o, (i.e., 1 mM, at which the CaSR is half-maximally active (14)) 
exposure to 1 µM ACh produced the expected increase in [Ca
2+
]i, which was significantly 
greater in ASM from asthmatic patients (Fig. 2C). Inhibiting CaSR with NPS2143 reduced 
the [Ca
2+
]i response to ACh to levels that were not significantly different from those 
measured in healthy ASM (Fig. 2C and Fig. S3C). These effects was even more pronounced 
in the presence of 2 mM Ca
2+
o, a concentration at which the CaSR is fully active, while they 
could not be observed in the presence of 0.5 mM [Ca
2+
]o, which is below the threshold for 
CaSR activation (Fig. S3C).  
Histamine (1 µM) also evoked an increase in [Ca
2+
]i in both healthy and asthmatic ASM, 
which was significantly greater in asthmatic ASM (Fig. 2D). Importantly, pre-exposure of 
asthmatic ASM to calcilytic also reduced [Ca
2+
]i responses to histamine so that they did not 
to differ statistically from those in healthy ASM (Fig. 2D). Furthermore, an alternative, 
membrane-impermeant CaSR agonist, Gd
3+
 (0.1 mM), evoked a further increase in [Ca
2+
]i in 
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human ASM either in the absence (Fig. S3D) or presence (Fig. S3E) of histamine, effects 
which were greater in asthmatic than in non-asthmatic ASM cells. Together, these results 
demonstrate that, in ASM cells, the CaSR is functional and contributes to the regulation of 
baseline ASM [Ca
2+
]i. Accordingly, in asthmatic ASM cells, the CaSR may contribute to a 
higher baseline [Ca
2+
]i, a leading cause of AHR, whereas calcilytics restore baseline [Ca
2+
]i.  
 
Calcilytics abrogate signaling pathways characteristic of airway contractility and asthma 
in human ASM 
To determine potential mechanisms by which CaSR modulates contractility relevant to 
asthma, we explored two mechanisms in non-asthmatic and asthmatic ASM: cAMP, which 
should induce bronchodilation, and phospholipase C (PLC)/IP3 an important contributor to 
bronchoconstriction, with the idea that CaSR activation should suppress cAMP but elevate 
IP3 (16). Indeed, in the presence of 2 mM Ca
2+
o, cAMP levels were low, and calcilytics 
increased cAMP, particularly in asthmatic ASM (Fig S3F). Measurements of cellular IP3 
content showed that, particularly in asthmatic ASM, CaSR antagonist suppressed the elevated 
levels of IP3 in the presence of 2 mM Ca
2+
o (Fig S3G).  
In addition to targeting phosphodiesterases to inhibit cAMP breakdown, many of the pipeline 
or existing drugs for asthma target activation of signaling pathways dependent upon ERK1/2, 
p38 MAPK, and PI3K/Akt phosphorylation (26, 27). Therefore, we examined the effect of 
activation of the ASM CaSR on these pathways in human ASM cells. In healthy ASM, CaSR 
activation with 5 mM Ca
2+
o induced a significant increase in p38 MAPK phosphorylation, an 
effect which was prevented by co-incubation with a calcilytic. Calcilytic treatment reduced 
ERK1/2 and Akt phosphorylation at 5 mM Ca
2+
o (Fig. 2E,F and Fig. S4 for technical 
replicates). Overall, these data highlight the ability of CaSR to modulate signaling pathways 
activated during asthma, which may contribute to altered ASM function beyond [Ca
2+
]i.  
 
SM22a
CaSR
∆flox/∆flox
 mice are protected from polycation-induced bronchoconstriction  
To determine whether activation of the CaSR in ASM leads to AHR in vivo, we generated 
mice with targeted CaSR ablation from visceral SM cells by breeding LoxP-CaSR mice with 
SM22-Cre mice(28, 29). The resulting SM22aCaSR∆flox/∆flox mice (knock out, KO, Fig. S5) 
were comparable to Cre-negative (wild-type, WT) littermates in appearance, reproductive 
abilities, body weight and life expectancy (Fig. S5 B,C). FACS analysis shows that molecular 
CaSR ablation from ASM resulted in a significant reduction in CaSR immunoreactivity in 
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KO cells, which was 27% of that seen in WT cells. In contrast, CaSR ablation from ASM 
cells did not significantly alter the expression of the smooth muscle marker, SM22α (Fig. 
S5D). Successful ASM CaSR ablation was demonstrated functionally by the evidence that 
Ca
2+
o (1-5 mM) and an alternative, membrane-impermeant CaSR agonist, Gd
3+
 (100 µM-
1mM), evoked an increase in [Ca
2+
]i in WT ASM cells, which was significantly greater than 
that measured in cells from KO mice (Fig. S5E, upper panels for single traces, and lower 
panels for biological replicates). Nevertheless, lungs from KO mice appeared 
histomorphologically comparable to those of WT mice and did not exhibit fibrosis, 
inflammation or impaired alveolarization (Fig. S5F). Intralobular bronchi from WT and KO 
mice also had comparable luminal diameters (Fig. S5G).  
 
Intrinsic baseline contractility of the intralobular bronchi was not affected by CaSR ablation 
from ASM cells, as shown by exposure to either high K
+
 (40 mM, Fig. S5H) or to increasing 
concentrations of ACh (1 nM - 30 µM), both of which evoked bronchoconstriction of 
comparable magnitude in WT and KO mouse bronchi (Fig. 3A). In intralobular bronchi from 
WT mice, treatment with either spermine (300 µM, Fig. 3B) or 2.5 mM [Ca
2+
]o (Fig. 3E) 
enhanced the bronchoconstrictor response to ACh. CaSR ablation from ASM blunted both 
spermine- (Fig. 3C) and [Ca
2+
]o- (Fig. 3F) induced sensitization of the ACh response. 
Furthermore, spermine (10 µM – 3 mM) induced sensitization of the ACh response in pre-
contracted WT, but not in KO mouse bronchi (Fig. 3D). Consistent with these findings, 
spermine also enhanced the response to ACh (0.5 µM) in precision-cut lung slices from WT 
animals (Fig. 3G, and summary in Fig. 3H). This effect was prevented by calcilytic treatment 
(NPS89636, 300 nM, Fig. 3H). However, the effects of either spermine or calcilytic were not 
observed in lung slices from KO mice (Fig. 3G, and summary in Fig. 3I). Taken together, 
these observations suggest that activation of the ASM CaSR leads to AHR, an effect which 
can be prevented by calcilytic treatment.  
 
Calcilytics reduce airway resistance in mixed allergen-sensitized mice in vivo 
To test the effects of pharmacological CaSR activators and inhibitors on pulmonary 
resistance, we directly measured airflow resistance (RL) in anaesthetized, paralyzed, 
mechanically ventilated mice. In naïve mice, acute pre-exposure (10 min) to the nebulized 
calcimimetic, R568 (1 µM), resulted in an increase in RL across the lungs following 
inhalational challenge with the synthetic muscarinic receptor agonist, methacholine (MCh, 0 
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– 50 mg/ml), whereas the calcilytic NPS2143 (1 µM) was able to reverse this effect (Fig. 
4A). Next, we developed a novel, mixed allergen (MA) murine asthma model that leads to 
robust inflammation and remodeling in the lungs of MA-sensitized mice (Fig. S6). In these 
mice, there was a marked increase in RL following MCh challenge, and pre-exposure to R568 
resulted in an even greater increase in RL. Moreover, the calcilytic was able to significantly 
reduce AHR in these mice (Fig. 4B).  
 
Calcilytics reduce AHR and inflammation in ovalbumin-sensitised, ovalbumin-challenged 
mice in vivo 
Increased arginase activity drives AHR via the production of polyamines (4, 5, 11), but 
whether the CaSR is involved in this process is unknown. To test the ability of calcilytics to 
prevent polycation-induced AHR in vivo, the effects of nebulized PLA (3 µM) were assessed 
in the presence or absence of the calcilytic NPS89636 (3 µM). As an alternative, non-
invasive method for measurement of AHR (30, 31), we performed whole-body 
plethysmography in conscious, unrestrained naïve mice by measuring enhanced pause 
(Penh). While Penh does not directly measure airway resistance, particularly in obligate nasal 
breathers such as mice, it has been widely used as an indicator of airway obstruction in 
response to inhaled MCh (0.1 - 100 mg/ml) (31). PLA significantly increased Penh at MCh 
concentrations greater than 10 mg/ml, an effect that was abolished by co-treatment with the 
nebulized calcilytic. Calcilytic treatment per se significantly reduced Penh in naïve animals 
treated with 30 mg/ml MCh (Fig. 5A).  
 
Having demonstrated the ability of calcilytics to reduce AHR evoked by polyamines, we 
tested their anti-inflammatory properties in an established model of allergic asthma (31), the 
ovalbumin (OVA)-sensitized, OVA-challenged mouse. Calcilytic inhalation significantly 
reduced AHR induced by OVA sensitization (Fig. 5B). Importantly, bronchoalveolar lavage 
fluid (BALF) collected from the calcilytic-treated mice also showed a significant reduction in 
inflammatory cell infiltration (total numbers, macrophages, eosinophils and lymphocytes, 
Fig. 5C), and concentrations of ECP, IL-5, IL-13 and TNF- (Fig. 5D) when compared to 
their vehicle-treated counterparts. Biochemical analysis of terminal blood samples showed 
that inhaled calcilytic did not significantly affect serum ionized calcium at 1 hour after 
inhalation (Vehicle control: 0.9 ± 0.1 mM vs. calcilytic 0.8 ± 0.1 mM, P > 0.05, N = 3 per 
experimental group); and up to 24 hours (1.0 ± 0.1 mM and 1.0 ± 0.1, four and 24 hours after 
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calcilytic treatment, respectively, P > 0.05, N = 3 per experimental group). These results 
suggest that the observed effects of the calcilytics are not ascribed to systemic changes in 
Ca2+o homeostasis. 
 
Discussion  
Our study is the first to highlights the expression of the CaSR in ASM, and to identify a 
fundamental pathophysiological role for this receptor in the context of asthma. The fact that 
inflammatory cationic proteins known to correlate with asthma severity can activate the 
CaSR expressed by ASM cells at physiologically relevant concentrations to elevate [Ca
2+
]i 
and increase the contractility of the ASM non-specifically provides both a rational 
explanation for the genesis of non-specific AHR in asthma and a basis for the direct 
mechanistic link between this phenomenon and airways inflammation. These findings raise 
the possibility that the CaSR directly influences mechanisms involved in inflammatory cell 
recruitment and activation. In turn, production of asthma-relevant cytokines can further 
increase CaSR expression, thereby generating a positive feedback loop. Thus, locally 
delivered calcilytics would have the advantage of both breaking this cycle by reducing 
inflammation, and by blunting ASM hyperresponsiveness. Indeed, in two different in vivo 
models of allergic asthma, interfering with CaSR signaling positively impacts on multiple 
aspects of airway disease, benefits not achieved by single-drug therapies. In this sense, the 
CaSR represents a truly novel potential therapeutic target in asthma. 
 
[Ca
2+
]o is known to be increased at inflammation sites (18, 32), therefore activating the CaSR, 
leading to an increase in [Ca
2+
]i and p38 MAPK activation and decrease in the intracellular 
cAMP pool. In addition, the CaSR is activated by a plethora of molecules, particularly 
polyamines, which act orthosterically (independently of [Ca
2+
]o) to help stabilize the unique 
conformations of the receptor. This leads to preferential coupling to different G proteins, a 
process defined as ligand-directed targeting of receptor stimulus (33). The relevance of the 
CaSR to local and systemic symptoms in asthma and other airways diseases is potentially 
immense, extending beyond its innate expression in ASM and any local regulation of [Ca
2+
]o. 
In asthma, airway inflammation leads to increased release of polycations, which are accepted 
markers of asthma severity, locally and into the systemic circulation (2-7). Sputum ECP 
concentrations in asthmatics have been reported to attain approximately 10 μg/ml (6, 7), 
which here we show to be well within the concentration range sufficient to activate the CaSR. 
Added to this is arginase-driven production of spermine, spermidine and putrescine, which 
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are increasingly implicated in asthma pathophysiology (4, 5, 11). From an environmental 
perspective, CaSR agonists may also be presented to the airways in the form of smoke (Ni
2+
) 
or car fumes (Pb
2+ 
and Cd
2+
) (34), and bacterial/viral infections (polyamines) (22, 23).  
 
In addition to elevating [Ca
2+
]i and, therefore, priming ASM cells to respond with a lower 
threshold to pathophysiological stimuli, CaSR may also enhance sensitization of airways to 
Ca
2+
, e.g. via coupling to PKC and Rho kinase, as demonstrated in other cell systems, namely 
HEK-CaSR (35), a topic that is currently unexplored in the lung, but is highly relevant to the 
increasing interest in targeting sensitization mechanisms (36). Beyond contributions to AHR 
and airway remodeling (25), calcilytics prevent activation of intracellular pathways which are 
currently being targeted by pipeline asthma drugs, specifically p38 MAPK and 
phosphodiesterase inhibitors (26). Indeed, both classes of inhibitors target various 
inflammatory cells, which release key mediators responsible for the remodeling and 
inflammation characteristic of these diseases. For this reason, local delivery of calcilytics has 
the potential to target not only one of the key possible causes for asthma, but also the 
production of pro-inflammatory cytokines that contribute to its exacerbations. Consistent 
with this hypothesis is the ability of the calcilytics to reduce inflammatory cell infiltration in 
the BALF of OVA-sensitized mice. 
 
Our ex vivo experiments show that activation of the airways CaSR increases responses to 
bronchoconstrictors by approximately 20-25%. Albeit apparently small, this effect is 
substantial if we consider that resistance to the air flow increases to the reciprocal of the 
fourth power of the bronchial radius. Indeed, direct measurements of airway resistance in 
naïve animals show that CaSR activators increase RL by roughly three folds. Thus, 
antagonizing the CaSR might provide a highly beneficial maneuver for the treatment of AHR 
in vivo. 
 
Individually, each of the approaches used in the current study has its inherent limitation. 
Concerning the ex vivo studies, wire myography records small airway tension in isolation 
and, although lung slices allow airway lumen size measurements in a system where the local 
paracrine environment is intact, there is no active innervation. For in vivo studies, FlexiVent 
data are obtained in anaesthetised mice, which are mechanically ventilated and, even though 
whole animal plethysmography records lung function in freely moving, spontaneously 
breathing animals, it can only report indirectly on airways resistance. However, this broad set 
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of experimental approaches has generated complementary data sets which, as the complexity 
of the measuring systems steadily builds, have provided comprehensive, overlapping 
evidence to show calcilytic-dependent diminution of airways responsiveness in normal and 
pathological paradigms. This idea is central to the thesis that locally delivered calcilytics may 
represent a brand new therapeutic approach to the treatment of asthma. 
 
Asthma represents a multi-factorial disease, involving many cell types in the airway beyond 
immune cells, including the epithelium and ASM. Accordingly, the expression and potential 
role of CaSR in cells of the airways becomes important. While our study focused on the 
ASM CaSR, it is worth noting that our observations demonstrate CaSR expression in airways 
epithelial cells. Epithelial cell damage is pathognomonic of asthma, while the presence of 
environmental polyamines and other CaSR activators might directly activate a functional 
epithelial CaSR, which might in turn contribute to airways remodeling and altered epithelial 
permeability in asthma, as demonstrated by CaSR activation in other epithelia (16). On the 
other hand, CaSR is functionally expressed in human and mouse macrophages, where it plays 
a crucial role in activation of NLRP3 inflammasome and release of IL-1β (17, 18), known to 
be involved in asthma pathogenesis. In addition, we found CaSR expression in human 
eosinophils (Fig. S7) and previous studies have shown that eosinophil degranulation (37) and 
migration across the lung epithelium (38) is also Ca
2+
o dependent. While our data clearly 
show a role for the ASM CaSR, particularly in the context of airway inflammation and 
asthma, given the expression of CaSR on both immune and epithelial cells, exploring their 
role will be important in future studies in the context of identifying CaSR modulators to 
alleviate AHR and allergic asthma. 
 
Owing to their ability to evoke rapid fluctuations in plasma PTH, a known anabolic stimulus 
to bone growth, systemic calcilytics were initially developed as anti-osteoporotic drugs and 
reached phase II clinical trials for this purpose in humans (39). Our in vivo data indicate that 
locally delivered calcilytics do not significantly affect plasma [Ca
2+
]o levels (hence 
presumably PTH levels) up to 24 hours post-treatment, suggesting that calcilytic 
administration directly to the lung in humans should not negatively impact on mineral ion 
homeostasis. 
 
A major implication of CaSR in the airway is its potential for targeting in the context of 
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disease. Accordingly, calcilytic-based therapeutics could do both, prevent as well as relieve 
AHR. What is unclear at present is whether CaSR overexpression and/or its responsiveness to 
polycations and calcilytics is uniform across the entire spectrum of asthma, particularly in 
view of the understanding that severe asthma may differ in pathophysiology and 
responsiveness to conventional pharmacotherapy (40). This reservation notwithstanding, it 
would certainly seem likely that one appealing line of future research will be the possibility 
that the CaSR can contribute to the development of asthma in some patients by creating a 
permissive environment for polycation action, with the corollary that such patients can be 
identified and treated prophylactically. Furthermore, given the involvement of polycations in 
other environmental airway insults, such as from pollution and respiratory infection, one 
might speculate that the potential exists for CaSR-targeted approaches to alleviate other 
inflammatory airway diseases.  
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Materials and Methods  
 
Study Design 
The objectives of the study were to test the hypothesis that the CaSR is a potential anti-AHR 
and anti-inflammatory target for asthma therapy. 
For experiments in primary human ASM cells, all protocols were approved by the Mayo 
Clinic Institutional Review Board. Surgical lung specimens of patients undergoing lobectomy 
for focal, non-infectious disease were obtained and normal areas of 3
rd
 to 6
th
 generation 
bronchi identified, and dissected for further use. Patient clinical data (combination of 
physician diagnosis, pulmonary function tests including bronchodilator responses, imaging 
results) were used to identify those with moderate asthma vs. not. However, once these data 
were recorded, all patient identifiers were deleted, and samples stored and processed with 
unique number identifiers, preventing retrospective identification of patients. Accordingly, 
the protocol was considered “minimal risk” and did not require explicit patient consent. For 
both asthmatics (all moderate, N = 5) and non-asthmatics (“healthy”, patients with no 
documented history of asthma, N = 5), patient ages ranged from 40 - 80 years. Both groups 
included only those patients undergoing thoracic surgery for focal, non-infectious pathology 
(e.g. localized tumor with negative lymph nodes; bronchoalveolar carcinoma was excluded). 
Samples in either group were used for a range of experimental protocols, although not all 5 
patient samples were used for every protocol.  
All animal procedures were approved by local ethical review and conformed with the 
regulations of the UK Home Office and the Animal Care and Use Committees of all the 
participating institutions. Procedures were in strict accordance to the guidelines of the 
American Physiological Society. 
Mice with CaSR-targeted gene ablation from ASM cells were generated by breeding sm22α 
Cre recombinase mice (28), with LoxP CaSR (flanking exon 7 of CaSR) (29). The floxed 
CaSR mouse strain was generated from C57BL/6 x SVJ129 mice backcrossed with C57BL/6 
for at least 8 generations. SM22α-Cre+ were bred with floxed-CaSR+/+ to generate 
SM
CaSR
∆flox/∆flox
 mice (lacking full-length CaSR in ASM), which were used as KO mice and 
SM22α-Cre-/- x floxed-CaSR+/+ (expressing full-length CaSR in ASM) acted as WT, control 
mice. CaSR-LoxP x SM22α-Cre mice were inbred for at least 3 generations before being 
used for experiments. Both WT and KO mice are fertile, and viable with a normal lifespan 
(Fig. S5 B,C). For the mixed allergen model, 6-8 week C57/Bl6 mice were purchased from 
Jackson Laboratories (Bar Harbor, Maine), and for non-invasive Penh measurements, 6-8 
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week BalbC male mice were used (Harlan). For laser-capture microscopy experiments, lungs 
from four mice (10 airways per mouse) were used. For Ca
2+
i imaging in human ASM, wire 
myography and lung slice experiments, based on our previous experience a minimum of 3 
patients per condition (at least 15 cells per experiment per patient) or a minimum of three 
mice per genotype are required to achieve statistical significance. For experiments in human 
ASM, wire myography, lung slices and in vivo plethysmography, lack of responses to ACh 
(in vitro and ex vivo experiments) or MCh (in vivo experiments) were a pre-established 
exclusion criterion, as was obvious epithelial damage or denudation in lung slice experiments 
when samples were observed under light microscopy. Data are presented as average ± 
standard error of the mean (S.E.M.), which was calculated invariably from N (the number of 
patients or animals, biological replicates), with the exception of western analysis of Akt, p38 
MAPK and ERK1/2 phosphorylation, where n represents the number of individual 
experiments (technical replicates). Animals were assigned to the experimental groups at 
random but the investigators were not blinded. Where appropriate, data were tested for 
normality (Shapiro-Wilk test).  
 
In vitro studies 
Human ASM cells: Human ASM cells were isolated and cultured as previously described (41) 
in DMEM/F12 (Life Technologies) supplemented with 10% fetal bovine serum, penicillin, 
and streptomycin. Culturing was limited to <4 passages and retention of the ASM phenotype 
was verified by expression of smooth muscle cell markers SM22α or calponin.  
HEK-293 studies: Cells stably transfected with human CaSR (HEK-CaSR) or empty vector 
(HEK-0, negative control) were generated and cultured as described previously (42). All cells 
tested negative for mycoplasma.  
Mouse ASM cells: Cells were obtained using previously described techniques (43). Passage 
1-4 cells were serum-starved for 24 hours prior to experimentation.  
Ca
2+
i imaging: Techniques using the ratiometric Ca
2+
 indicator fura-2 AM have been 
previously described (25, 41). An inverted microscope (Olympus IX71, Southend-on-Sea, 
United Kingdom) and fluorescence source (Xenon arc or LED) along with rapid perfusion 
system was used to alter [Ca
2+
]o (1-5 mM), add agonists (ACh, histamine), Gd
3+
 (100 M-
1mM) or add the polycations ECP (10 mg/ml), PLA (300 μM) or spermine (1 mM). During 
experimentation requiring different [Ca
2+
]o, these changes were made ~30 min prior to 
experiment (but after dye loading to ensure no confounding effects of Ca
2+
o on CaSR or on 
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the loading per se). Where stated, cells were incubated with calcilytics (NPS89636, NPS2143 
or Calhex) for 20 minutes.  
pAkt, p38
MAPK
 and pERK cell signaling: Human ASM isolated from two healthy subjects (n = 
17-19 technical repeats) were passaged up to 10 times and plated for phosphorylation 
experiments. Cells were exposed to 0.5 mM Ca
2+
o (control), 5 mM Ca
2+
o or 5 mM Ca
2+
o in 
the presence of NPS2143 (1 μM) experiments were carried out and as described previously 
(44). 
Protein analysis: Standard SDS-PAGE with 4-15% gels and PVDF membranes were used 
with protein detection using far-red (LiCor Odyssey XL) or HRP-conjugated secondary 
antibodies. CaSR protein expression was normalized to GAPDH. 
 
Ex vivo studies 
Force measurements in intralobular bronchi: 2
nd
-3
rd
 order intralobular bronchial rings (2 mm 
length) were isolated from the left lobe, cleaned and mounted in a wire myograph (610 M, 
DMT) for measurement of isometric force as described previously (45) at a passive tension of 
2 mN. For the non-paired experiments (WT vs. KO), the data were normalized to the mean 
maximum for WT, whilst for the paired experiments (control vs. treated with spermine or 
high [Ca
2+
]o) each data point was normalized to the maximum of its own control. To obtain 
the spermine concentration-response curve, bronchi were first pre-contracted with ACh to 
achieve approximately 50% of maximal tone, then rising concentrations of spermine were 
added to the bath. The averaged data points of each set were fitted with sigmoidal dose-
response curve, variable slope (ACh), or second order polynomial curve (spermine). 
Precision-cut lung slices: Samples were prepared as previously described (46). Intralobular 
bronchi were identified under light microscopy (Nikon Diaphot) and imaged during 
bronchoconstrictor stimulation. Bronchial lumen areas were measured with ImageJ. Tone 
was established using 1 μM ACh and the effects of polyamine spermine (300 μM) were 
determined in the absence and presence of calcilytic NPS89636 (300 nM).  
Laser capture microdissection (LCM) and quantitative RT-PCR: Air-inflated lungs from 
control and mixed allergen challenged cohort of mice were rapidly frozen under RNase-free 
conditions (47). Samples were cryosectioned and total RNA was isolated as described 
previously (47). CaSR mRNA was standardized against ribosomal protein S16 mRNA (ΔCt). 
Individual ΔCt values were standardized against mean Ct of the control group (non-
asthmatic humans and control mice, Ct) on which statistical comparisons were performed. 
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For graphical representation, the mean fold difference ± SD between the groups was 
calculated as 2
-ΔΔCt ± SD
. 
Immunofluorescence: Standard techniques were applied to cryosections of 
paraformaldehyde-fixed biopsies from human lung and vibratome-cut, paraformaldehyde 
post-fixed murine lung slices. A TCS-SP2 AOBS confocal laser-scanning microscope (Leica) 
was used for image acquisition.  
 
In vivo studies 
Measurements of airway resistance (RL): RL was measured by FlexiVent (Montreal, Canada) 
under pentobarbital anesthesia and pancuronium paralysis using established techniques (47, 
48). In select cases, animals were pre-nebulized with the CaSR positive (R568; 1 M) and/or 
negative (NPS2143; 1 M) allosteric modulators (Tocris) 10 min prior to MCh challenge.  
Mixed allergen model: each C57Bl6 mice received daily intranasal mixture of 10 μg of OVA, 
and extracts from Alternaria, Aspergillus and Dermatophagoides (house dust mite) for 4 
weeks (Greer Labs), each dose in 50 µl in PBS. Control mice received intranasal PBS. 
Animals were analyzed 24h after the last sensitization.  
Whole-body plethysmography: Non-invasive barometric plethysmography (Buxco Research 
Systems) was carried out in unrestrained, conscious mice as described previously (31). 
Following establishment of baseline enhanced pause (Penh) (49) standard nebulized 
methacholine challenge was performed (0.1-100 mg/ml in saline; 3 min recording/dose; 
Pulmostar nebulizer, Sunrise medical), and Penh values calculated and expressed as 
percentage change (Δ Penh, %). While the physiological data provided by a Penh-based 
approach differs from that using the forced-oscillation technique of the FlexiVent system, the 
non-invasive approach allowed for longitudinal measurements of baseline and chronic drug 
effects in the same animals (as below).  
Polycation-induced AHR: 24 hours following baseline measurements of Penh with MCh 
challenge, mice were exposed to aerosolized PLA (3 M), NPS89636 (3 M), PLA + 
NPS89636 or vehicle (0.3% DMSO, v/v) for 1 h and MCh challenge repeated. For 
experiments with PLA + NPS89636 or vehicle, mice were pre-treated for 30 min with 
NPS89636 (or vehicle) and then co-treated with PLA. Mice were allowed to recover for 1 
week between each set of experiments. Separately, naïve animals were exposed to nebulized 
NPS89636, and 0, 4, and 24 hours later the blood collected and analyzed for serum Ca
2+
. 
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OVA–induced AHR: Male BalbC mice were sensitized on day 0 and 5 by i.p. injection of 
100 μg/mouse OVA and 50 mg/mouse aluminum hydroxide in PBS. Thirteen days after the 
final injection, Penh was recorded during MCh challenge. The next day, mice were 
challenged twice with 0.5% nebulized OVA (in PBS w/v) and nebulized NPS89636 (3 M, or 
0.03% DMSO vehicle) by inhalation, 4 hours apart. 29 hours after the first OVA inhalation, 
Penh was again recorded during MCh challenge.  
BALF analysis: Bronchoalveolar lavage was performed after the terminal experiment and 
cells were isolated by CytoSpin centrifugation (Thermo Scientific) and total and differential 
cell counts performed following Leishman’s staining. ELISA (R&D) and ECP (Aviscera 
Bioscience Inc) measurements were performed according to the manufacturer’s instructions. 
 
Materials and antibodies 
NPS89636 was a gift from NPS Pharmaceuticals, Inc. NPS2143 and Calhex231 was 
purchased from Tocris. All other chemicals were purchased from Sigma-Aldrich, unless 
otherwise stated. Primary antibodies used were: anti-SM22α (Abcam); anti-CaSR (AnaSpec, 
or Abcam); anti-phospho ERK, anti-phospho Akt and anti-p38 MAPK (Cell Signalling). 
Secondary antibodies used were: Alexa Fluor 488, and Alexa Fluor 594 or Alexa Fluor 647 
(Life Technologies). Nuclei were counterstained using Hoechst. Omission of the primary 
antibodies acted as negative control. 
 
Supplementary Materials 
 
Materials and Methods 
Fig. S1. Negative controls and original western blots for Fig. 1 
Fig. S2. Polycations increase [Ca
2+
]i in by acting on the human CaSR  
Fig. S3. Calcilytics prevent CaSR activation in human asthmatic ASM  
Fig. S4. Technical replicates of data presented in Fig. 2F 
Fig. S5. Phenotypic characterization of the 
SM22a
CaSR
∆flox/∆flox
 mouse 
Fig. S6. Validation of the mixed allergen asthma model 
Fig. S7. CaSR expression in human eosinophils 
Database S1. Source data for Fig. 1 to 5 and Fig. S1 to S5 (provided as Excel file) 
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Statistics 
Statistical significance was determined using Graph Pad Prism 6 software. Student’s two-
sided, unpaired or paired t-test was used to compare a group of two data sets, one-way or 
two-way ANOVA with Bonferroni post hoc test, or non-parametric (Friedman) with Dunn 
post hoc test, as stated in figure legends, used to compare three or more data sets. Where 
applicable, statistical comparisons were made between non-normalized data groups, but 
normalized data are presented in the figures. 
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Figure 1. CaSR immunolocalizes to human and mouse airways and is over-expressed in 
asthma  
(A) Human airway biopsy (upper panels) or mouse intralobular bronchi (lower panels) 
stained with CaSR antibody (red) and SM22α (green) show immunoreactivity in both smooth 
muscle and epithelium (scale bar = 10 μm). (B) Human and mouse ASM cells stained with 
anti-SM22α antibody and showing CaSR immunoreactivity (bar = 100 μm). (C) Quantitative 
RT-PCR shows higher CaSR expression in moderate asthmatics than in healthy subjects (N = 
4 patients per group, fold change vs. healthy, mean (line) ± SD (box). (D) Western analysis of 
CaSR protein shows substantially elevated CaSR expression in moderate asthmatics (N = 5 
patients per group). (E) Exposure of healthy human ASM cells to TNF (20 ng/ml) or IL-13 
(50 ng/ml) for 48h significantly increased CaSR protein expression (N = 5 patients per 
group), compared to vehicle control for either cytokine. (F) CaSR mRNA expression was 
significantly greater in mice following induction of airways inflammation with mixed 
allergens in comparison to unsensitized mice (N = 4 mice per group; 10 airways/mouse, fold 
change vs. unsensitized, mean (line) ± SD (box). Statistical comparisons were performed (on 
ΔΔCt values for C and F) by two-tailed, unpaired Student’s t-tests (C, D and F) and one-way 
ANOVA with Bonferroni post hoc test (E). *P < 0.05, **P < 0.01, ***P < 0.001 vs. healthy, 
control or unsensitized, as shown. Source data, details of the statistical analysis and P values 
are given in the Supplementary Materials.  
 
Figure 2. Polycations activate the human CaSR in recombinant systems and human ASM 
cells, particularly those from asthmatics 
(A) ECPs (N = 7), poly-L-arginine (PLA, N = 6) or spermine (N = 17) each increased [Ca
2+
]i 
in HEK-CaSR, but not in HEK-0 cells (ECP, N = 3; PLA, N = 6; spermine, N = 6). In HEK-
CaSR cells, the calcilytic NPS89636 prevented these increases (ECP, N = 3; PLA, N = 3, and 
spermine, N = 4). Two alternative calcilytics, NPS2143 (N = 4) or Calhex 231 (N = 5) also 
prevented spermine-induced CaSR activation. (B) In human ASM cells, exposure to at 2 mM 
[Ca
2+
]o increased [Ca
2+
]i in asthmatics, but not healthy ASM (B, left), an effect prevented by 
the calcilytic, NPS2143 (B, right) (N = 3 each). (C, D) In the presence of 1 mM Ca
2+
o, 
exposure to ACh (C, N = 4 healthy, N = 4 asthmatic) or histamine (D; N = 5 healthy, N = 4 
asthmatic) resulted in increases in [Ca
2+
]i, which was greater in asthmatic ASM cells. This 
effect was prevented by NPS2143. (E, F) Western analysis (exemplar gel (E) and summary 
data (F)) of healthy ASM cell lysates show the effects of 5 mM Ca
2+
o in the absence or 
presence of NPS2143 on Akt, p38 MAPK and ERK phosphorylation (n = 17-19 independent 
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experiments from cells isolated from N = 2 non-asthmatic patients). Statistical significance 
was determined by one-way ANOVA, Bonferroni post hoc test (A), two-way ANOVA, 
Bonferroni post hoc test (B-D), or one-way ANOVA with Dunn post hoc test (F). *P < 0.05, 
**P < 0.01, ***P < 0.001, significantly different from control HEK-CaSR (A), from control 
healthy or asthmatic ASM (B-D), or from 5 mM Ca
2+
o (B). Source data, details of the 
statistical analysis and P values are given in the Supplementary Excel spreadsheet. 
 
Figure 3. CaSR ablation from airway smooth muscle cells blunts polycation-induced 
bronchoconstriction 
Tension measurements in intralobular bronchi from mice with targeted CaSR ablation from 
ASM cells (
SM22a
CaSR
∆flox/∆flox
, KO) and from SM22a-Cre mice (WT) (A-F). (A) In control 
conditions, bronchial contractility to ACh was not affected by CaSR ablation (WT, N = 14; 
KO, N = 12). Exposure to spermine enhanced contractility to ACh in WT (B, N = 6), but not 
in KO mice (C, N = 7). (D) Spermine alone induced constriction in WT but not in KO mouse 
intralobular bronchi, which was significant at 1 mM (WT, N = 4; KO, N = 7) and above 
(WT, N = 3; KO, N = 7). The sensitivity to ACh was increased when [Ca
2+
]o was raised from 
the physiological 1 to 2.5 mM in WT mice (E, N = 6), but not in KO mice (F, N = 7). In 
precision-cut lung slices from WT mice, ACh-induced contraction of intralobular bronchi 
was potentiated by spermine and prevented by the calcilytic NPS89636 (G, upper panels, 
representative of 7 experiments; summary in H; N = 7), while there was no spermine 
potentiation or calcilytic effect in KO mice (G, lower panels, representative of 4 experiments; 
summary in I; N = 4). Scale bar = 100 µm. Statistical comparisons made by two-way 
ANOVA (A-F, between curves and for WT vs. KO for identical agonist concentrations) or 
two-tailed, paired Student’s t test (H, I, performed on the non-normalized data); *P < 0.05, 
**P < 0.01, ***P < 0.001 statistically different from respective WT controls. Source data, 
details of the statistical analysis and P values are given in the Supplementary Materials. 
 
Figure 4. Activation of the airways CaSR exacerbates AHR in vivo.  
(A) In mechanically ventilated, unsensitized mice, acute exposure to the calcimimetic R568 
increased bronchoconstriction to MCh challenge, measured as increased airway resistance 
(RL). The calcilytic prevented the AHR induced by R568, but evinced little effect on its own. 
(B) Mixed allergens (MA)-sensitized mice showed enhanced response to MCh. Pre-exposure 
to the calcimimetic resulted in a further increase in RL whilst the calcilytic NPS 2143 reduced 
AHR. Statistical comparisons between the curves were made by two-way ANOVA, 
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Bonferroni post hoc test. N = 5 per condition; **P < 0.01, ***P < 0.001 statistically different 
from control, 
###
P < 0.001 statistically different from calcimimetic. Source data, details of the 
statistical analysis and P values are given in the Supplementary Materials. 
 
Figure 5. Nebulized calcilytics prevent AHR and inflammation in mice in vivo 
(A) Nebulized calcilytic (NPS89636) prevented PLA-induced AHR in unsensitized, 
conscious mice. Data are presented as percentage changes in enhanced pause, Penh (Penh, 
%), in MCh-challenged mice (N = 6 mice per condition). Calcilytic abrogated 
hyperresponsiveness (B, N = 5 for control, N = 6 each for vehicle and calcilytic), reduced 
inflammatory cell infiltration (C, N = 11) and the concentrations of ECP (N = 11), IL-5, IL-
13 and TNF (D, N = 10 for vehicle, and N = 11 for calcilytic) into the BALF from OVA-
sensitized, OVA-challenged mice. *P < 0.05, **P < 0.01, ***P < 0.001 statistically different 
from vehicle control; #P < 0.05, ###P < 0.001, statistically different from treatment with PLA. 
For (A) and (B), statistical comparisons were made by two-way ANOVA, Bonferroni post-
hoc test. For (C) and (D), statistical significance was determined by two-tailed, unpaired 
Student’s t-test. Source data, details of the statistical analysis and P values are given in the 
Supplementary Materials. 
 
 
  
  
 27 
Figure 1 
 
  
 28 
Figure 2 
 
  
 29 
Figure 3 
 
  
 30 
Figure 4 
 
  
 31 
Figure 5 
 
